OncoMatch/Clinical Trials/NCT06775080
The Use of Propranolol in the Perioperative Period of Resectable Gastrointestinal Tumors
Is NCT06775080 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies propranolol (beta-blocker used treat high blood pressure) for gastrointestinal tumors.
Treatment: propranolol (beta-blocker used treat high blood pressure) — In this study, perioperative propranolol β-blockade was administered to patients with surgically resectable primary gastrointestinal tumors to explore the safety, efficacy, and alleviation of perioperative psychological stress. At the same time, a multi-omics study was conducted using clinical samples to explore the activation of anti-tumor immune response and its mechanism.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Gastric Cancer
Hepatocellular Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Esophageal Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: surgery
Patients who have undergone surgery for GI tumors within the previous six months
Cannot have received: neoadjuvant chemotherapy
Patients receiving neoadjuvant chemotherapy prior to planned gastrointestinal tumor resection
Lab requirements
Kidney function
creatinine clearance ≤ 0.15 mmol/L
Liver function
AST or ALT or ALP ≤ 2.5x ULN, bilirubin ≤ 1.5x ULN
Cardiac function
Resting blood pressure > 100/60 mmHg, heart rate > 60 beats per minute; exclusion for pathological sinus node syndrome, sinus bradycardia (<60 bpm), AV block (any degree)
Resting blood pressure greater than 100/60mmHg, heart rate greater than 60 beats per minute. Pathological sinus node syndrome; Sinus bradycardia (less than 60 beats/minute); First, second or third degree AV block; Resting blood pressure less than 100/60 mmHg; Patients with renal insufficiency (defined as creatinine clearance greater than 0.15 mmol/L); Patients with hepatic insufficiency: AST or ALT or ALP > 2.5 times the upper limit of normal (ULN), bilirubin > 1.5 times the ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify